GlassScriptPhysician profile
Jyoti Shah
NPI 1922027754
$4,682.72
in general payments reported to CMS, 2019-2025
42 companies · $894 in 2025
The $894 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,248 · 2020: $280 · 2021: $849 · 2022: $602 · 2023: $539 · 2024: $272 · 2025: $894.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,645 · Education: $58.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,645.36 |
| Education | $58.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,130.93 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $911.03 | 2019-2025 | Tezspire, Breztri, Fasenra |
| Insmed, INC. | $420.04 | 2019-2025 | Arikayce, Brinsupri |
| Genzyme Corporation | $230.95 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $182.74 | 2019-2024 | Dupixent |
| Sunovion Pharmaceuticals INC. | $159.87 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $118.31 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $106.63 | 2019-2025 | Ajovy, Austedo |
| Merck Sharp & Dohme LLC | $94.39 | 2021-2024 | Verquvo, Belsomra |
| Philips North America LLC | $81.25 | 2019-2021 | |
| Amgen INC. | $80.17 | 2019-2023 | Tezspire |
| Sanofi-Aventis U.S. LLC | $74.75 | 2022 | |
| Mylan Specialty L.P. | $74.65 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $74.41 | 2021 | |
| Mallinckrodt Hospital Products INC. | $71.92 | 2020-2022 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jyoti Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.